From the Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
To investigate the mechanisms of bradykinin
B1 (BKB1) receptor gene expression,
transient DNA transfection analyses of human BKB1 receptor
gene promoter were performed in SV-40 transformed IMR90 cells. A
positive regulatory element (PRE) located at position 604 to
448
base pair (bp) upstream of the transcription start site consistently
exhibited, by far, the highest level of relative luciferase activity. A
negative regulatory element, at position
682 to
604 bp, was able to
completely ablate the function of the PRE. Transfection combined with
deletion and mutation analyses illustrated that the PRE contains a
classic, powerful enhancer. This enhancer was minimized to a 100-bp
element at position
548 to
448 bp. A 78-bp fragment of negative
regulatory element functioned as a silencer. Transient transfection of
the enhancer construct, driven by heterologous herpes simplex thymidine
kinase promoter, into a variety of cell types, showed that this
enhancer presents a cell-type specific feature. In the characterization
of the enhancer, motifs A (
548 to
532) and B (
483 to
477) were
found to be essential for full enhancer activity. Motif D (
472 to
467) played a smaller role in enhancer activation. Gel shift and
antibody supershift assays determined that an AP-1 factor binds with
motif B. The nuclear protein which binds to motif A has yet to be
identified. Both factors are the critical regulators for this enhancer
activation.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bradykinin (BK)1
receptors are members of the G-protein coupled receptor family (1). A
large body of evidence points to the involvement of BK receptors in
inflammation and shock leading to hypotension and pain (2, 3). Two
subtypes of bradykinin receptor (BKB1 and BKB2)
with variable ligand binding affinity and different agonists and
antagonists have been characterized (2, 4-6). The BKB1
receptors are generally only minimally expressed under normal
physiological conditions. But functional BKB1 receptors are
rapidly induced under many inflammatory conditions such as arthritis,
cystitis, UV irradiation, colitis and hyperalgesia, and inflammation
(3, 7-11). However, these receptors are expressed only in a limited
number of human tissues such as lung, colon, stomach, and bladder (7,
8). In vitro studies have implicated LPS, PMA, and various
cytokines, such as interleukin-1 and interleukin-2, interleukin-8,
and interferon-
as effectors in the rapid induction of
BKB1 receptor expression (7, 8, 12-14).
The mechanism(s) leading to the rapid induction of this gene are unknown. Evidence suggests that the expression of BKB1 receptors is regulated at both transcriptional and post-transcriptional levels (3, 7, 8, 14). The genomic sequence of the human BKB1 receptor gene was recently reported by several groups including ours (6, 15, 16). So far neither detailed functional promoter structure nor the regulatory elements of this gene have been defined.
The aim of this study was to begin to characterize the functional promoter. We identified a powerful enhancer and certain crucial cis-acting regulatory elements of this gene. Initially, we used a transient transfection strategy to characterize the functional promoter and localize the important regulatory elements. By using deletion and mutation strategies, a minimum enhancer element and its regulatory sequence motifs were defined in the 5'-flanking region. Gel shift and antibody supershift procedures were then used to identify an AP-1 factor and another unknown factor as crucial transcriptional regulators of this enhancer.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Plasmid Constructs--
The BKB1 5'-flanking region
was previously isolated as a genomic clone (6). By subcloning and
sequencing we defined approximately a 1.8-kb fragment upstream of the
transcription start site. Its nucleotide sequence was submitted to
GenBank (access number U48827). A schematic representation of the
pGL-BK-LUC constructs is shown in Fig. 1. The pGL-BKA-LUC was generated
by using PCR to generate a 1.8-kb fragment from a subclone followed by
cloning into the SacI and HindIII sites of
pGL-3-Basic vector (Promega, Madison, WI) harboring a promoter segment
from
1,748 to +89. The PGL-BKB-LUC was constructed by SmaI
digestion of pGL-BKA-LUC to remove a 400-bp fragment. The other five
5'-end deleted constructs were generated by either standard restriction
enzyme digestion or PCR and were cloned into the pGL-3-Basic vector.
The exact end points of the deletions are presented in Fig. 1.
[[3H]des-Arg10]Kallidin Binding
Assay--
BKB1 receptor number was determined by binding
of [[3H]des-Arg10]kallidin to intact cells
in culture as described previously (17). Confluent cells in 24-well
plates were washed twice with 1 ml of binding buffer (0.05% (v/v)
bovine serum albumin, 2 mM bacitracin, 10 mM
Hepes (pH 7.3), 120 mM
N-methyl-D-glucamine, 0.65 mM
CaCl2, 0.25 mM MgCl2, 0.25 mM MgSO4) followed by a 15-min equilibration with 0.5 ml of cold binding buffer. The binding buffer was replaced with binding buffer containing 10 nM
[[3H]des-Arg10]kallidin. Nonspecific
binding was determined in the presence of 4.5 µM
unlabeled [des-Arg10]kallidin. After 2 h at 4 °C,
the cells were washed 3 times with 1 ml of wash buffer (binding buffer
supplemented with 0.15% bovine serum albumin). The cells were
solubilized with 0.25 ml of 0.2% SDS and radioactivity determined in a
-counter.
Cell Culture and Transfection--
The IMR90-SV40 (IMRSV) and
IMR90 cells were grown in minimal essential medium with 10% fetal
bovine serum. Rat-1 cells were grown in Dulbecco's modified Eagle's
medium with 5% fetal bovine serum. COS cells were grown in Dulbecco's
modified Eagle's medium with 10% fetal bovine serum. HEK 293 cells
were grown in Dulbecco's modified Eagle's medium high glucose with
10% fetal bovine serum. Cells were transiently transfected with 0.5 µg (for 2 cm2 wells) or 1.0 µg (for 4 cm2
wells) of DNA construct using the DNA-calcium phosphate precipitation method (18). Cytomegalovirus--galactosidase vector DNA was co-transfected as an internal control for transfection efficiency (25 ng for 2 cm2 wells or 50 ng for 4 cm2 wells).
After 16 h incubation with the transfection solution, the medium
was removed and replaced with fresh growth medium. Twenty-four hours
later the cell extracts were harvested for luciferase assays and
-galactosidase determination. In case of effector addition, 48 h after transfection the cells were washed two times with Hank's
balanced salt solution and then serum-free minimal essential medium was
added. The stimulators (LPS, 10 µg/ml, Difco; TNF-
, 5 ng/µl, R&D
System; PMA, 100 ng/ml, Sigma; Bradykinin, 1 µM, Sigma)
were added and retained in the culture medium for 4 h. Then the
cell extracts were harvested for luciferase assay. The luciferase
assays were performed according to the protocol from Promega.
Luciferase activities were determined in a 1011 LKB
-counter
equipped with a luminescence program.
-Galactosidase assays were
carried out according to the method from Maniatis et al.
(19). The luciferase activity data were normalized with
-galactosidase activity.
Nuclear Extract Preparation-- Nuclear extracts were prepared as described previously (20). The extracted nuclear protein concentration was determined by the BCA protein assay (Pierce, Rockford, IL).
Electrophoretic Mobility Shift Assay--
The synthetic
oligonucleotides were purchased from Life Technologies, Inc.
Complementary oligonucleotides were annealed and phosphorylated with T4
polynucleotide kinase in the presence of [-32P]ATP.
The following sequences represent the coding strands of electrophoretic
mobility shift assays probes and mutant competitors: probe A (BK
enhancer
553 to
528), 5'-CATAATTTGAGAGACGCCAAGGAGG-3'; probe B (BK
enhancer
497 to
472), 5'-CTCTGAACATTGCATGAGTCAAACG-3'; mutant 1, 5'-TTTGAGAGACAGACTGGAGGATTAGG-3'; mutant 3, 5'-GAACATTGCATCGCAGAAACGTTTTCC-3'. The nucleotide bases
underlined indicate the bases mutated, with regard to the probes used.
Consensus oligonucleotides for AP-1, AP-3, SP-1, and CTF were obtained
from Stratagene.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
BKB1 Receptor Gene Promoter Is Regulated by Both
Positive and Negative Elements--
The genomic structure of human
BKB1 receptor including part of the 5'-flanking region has
been reported recently (6, 15, 16). To date no information exists on
the characterization of this gene promoter or the mechanism of its
transcriptional regulation. To delineate the sequences essential for
transcription of the BKB1 receptor gene and identify
important regulatory domains, we cloned approximately a 1.8-kb fragment
of the 5'-flanking sequence from a -genomic clone (6). A series of
six 5'-end deletion mutants were generated. One additional construct
(pGL-BKB-LUC) was generated by a deletion between
1495 and
1092.
These constructs were transfected into IMRSV cells. Reporter gene
luciferase activities were measured. Several positive and negative
regulatory regions were identified (Fig.
1). Two positive regions were found at
nucleotide positions
730 to
682 and
604 to
448. Much lower
luciferase activities were observed when these regions were deleted.
Three negative regulatory regions (position
1745 to
730,
682 to
604, and
448 to
384) were identified. Deletion of these regions
resulted in a marked increase in luciferase activity. A strong positive element (PRE) located in position
604 to
448 proved of particular interest. This element produced a very large (over 34-fold) increase of
reporter gene expression. A strong negative element (NRE) was located
in the immediate upstream left of the PRE at position
682 to
604.
This element completely inhibited the function of the PRE. These
observations point to the presence of a dominant enhancer and a strong
silencer in the 5'-flanking region of the inducible BKB1
receptor gene.
|
The Expression Pattern of BKB1 Receptors in Different Cell Types-- Only a limited number of cell types and tissues have thus far been reported to express the BKB1 receptor (7, 8). Binding of [[3H]des-Arg10]kallidin to IMR90, IMRSV, HEK-293, Rat-1, and COS cells was performed to determine the expression of BKB1 receptor in these cell types. The results illustrated in Fig. 2 show that HEK-293, Rat-1, and COS cells do not exhibit endogenous BKB1 receptor binding. Whereas, IMR90 and IMRSV cells exhibit statistically significant endogenous BKB1 receptor binding.
|
Cell-type Specific Feature of cis-Acting Regulatory Elements in the Promoter of Human BKB1 Receptor Gene-- To determine whether the regulatory elements in this gene promoter have cell-type specific features, construct pGL-BKE-LUC (containing PRE no NRE) and construct pGL-BKB-LUC (containing PRE plus NRE) were transfected into several cell types. The transient transfection results illustrated in Fig. 3 show that the sizable increase in luciferase activity with the construct, pGL-BKE-LUC was exhibited only in IMR90 and IMRSV cells. Both cell types were also shown to bind [des-Arg10]kallidin (Fig. 2). Only limited increase in luciferase activity from the construct pGL-BKE-LUC was found in HEK-293 cells which did not bind with [des-Arg10]kallidin. Another construct, pGL-BKB-LUC, presented very low luciferase activity in all three cell types. These results illustrate that the activating function of PRE correlates with the presence of endogenous BKB1 receptors. NRE completely abolished the activating function of the PRE. A putative, positive regulator of BKB1 receptor transcription may exist in the cell lines presenting the endogenous BKB1 receptor; or an additional negative regulator is active in the cell types where no endogenous BKB1 receptor is expressed.
|
BKB1 Receptor Expression in IMRSV Is Regulated by a
Novel Enhancer Element in the 5'-Flanking Region of BKB1
Receptor Gene--
The PRE is a 156-bp fragment located at position
604 to
448 of the 5'-flanking region of this gene. The above
results, using transient transfection, suggest that PRE functions as an
enhancer element. To ascertain whether this fragment fulfills the
requirements of an enhancer, this 156-bp fragment was inserted into a
plasmid with a luciferase reporter gene driven by the herpes simplex
virus-TK promoter in either sense or antisense orientation, or with the fragment placed in the 3'-end of luciferase gene. As shown in Fig.
4, the luciferase activity of these
constructs showed a 19-, 20-, and 38-fold stimulation, respectively.
These results provide additional evidence that this 156-bp fragment
functions as a classic, powerful enhancer.
|
Identification of a Minimum Enhancer Element in the 5'-Flanking
Region of BKB1 Receptor Gene--
To minimize the
functional enhancer, a series of deletion fragments were generated by
PCR overlapping the PRE region. The fragments were subcloned into the
pGL-TK-LUC vector and transfected into IMRSV to measure reporter gene
luciferase activity. The results are shown in Fig.
5. Three constructs (604 to
362,
604 to
448, and
548 to
448) presented strong enhancer activity,
while three other constructs (
468 to
362,
548 to
491, and
508
to
448) only showed partial enhancer activity. The construct
(pGL-Be100-TK-LUC) containing a 100-bp fragment from position
548 to
448 presented the strongest enhancer activity. Further deletion of
5'-end after position
548, or further deletion of 3'-end before
position
448 reduced full enhancer activity. This suggests that the
100-bp fragment between
548 and
448 in the 5'-flanking region of
BKB1 receptor gene is the minimum enhancer element, the
nucleotides in both ends of this enhancer fragment are required for
full enhancer activation.
|
Cell-type Specific Feature of the BKB1Receptor Enhancer-- To determine whether the enhancer has cell-type specific function, constructs with/without the minimal 100-bp enhancer, driven by TK promoter, were transfected into IMR90, IMRSV, HEK- 293, Rat-1, and COS cells. Results shown in Fig. 6 proved very interesting. The enhancer fully activated the TK promoter in IMR90 and IMRSV cells. There was no enhancer activation in HEK-293, Rat-1, and COS cells. These results provide further evidence that there is a cell-type specific enhancer in the 5'-flanking region of the BKB1 receptor gene. The function of the enhancer correlates with the cellular expression of the BKB1 receptor.
|
Dissection of the 100-bp Enhancer Element Identifies Multiple
Positive Motifs Required for Full Enhancer Activity--
To
characterize the regulatory motifs of the 100-bp enhancer element, a
search for consensus sequences of transcription factors identified
several potential nuclear factor-binding sites. Some of the common
consensus sequences in the enhancer element are shown in Fig.
7A. An NF-1-like binding site
(motif A) is located at the 5'-end of the enhancer. An AP-1 site (motif
B) is located in the 3'-end of the enhancer. One PEA-3-binding site
(motif C, PEA-3A) is adjacent to the 5'-end of motif A
(NF-1-like site). Another PEA-3 site (motif D, PEA-3B) is
located adjacent to motif B (AP-1 site) in the 3'-end of the enhancer.
To determine whether any of these consensus sequences are essential for
the function of the enhancer, four mutants were generated by
site-directed mutagenesis using the enhancer as a template. The sense
strand oligonucleotides used for the mutagenesis are shown in Fig.
7A. These mutant constructs were transfected into IMRSV to
evaluate the enhancer activity. Results are shown in Fig.
7B. As compared with the original enhancer, less than 20%
of enhancer activity remained when motif A (NF-1-like site, 546 to
534) was mutated. Enhancer activity was almost eliminated when motif
B (AP-1 site,
485 to
477) was mutated. Moreover, further deletion
at the 5'-end and mutation of motif C (PEA-3A site) did not
show a meaningful change of reporter gene luciferase expression when
compared with the mutant activity where the NF-1-like site was mutated.
The 3'-end deletion and mutation of motif D (PEA-3B site)
did bring the relative luciferase activity down more than half but did
not abolish the enhancer activity. These observations suggest that motifs A, B, and D are required for full enhancer activity. Motifs A
and B play a major role in enhancer activation.
|
Specific DNA-Protein Interactions within Enhancer Region of Human BKB1 Receptor Gene in IMRSV Cells-- To examine the ability of the crucial motifs, A and B, to interact with transcription factors, two probes, assigned as A (overlapping the motif A) and B (overlapping the motif B), were synthesized and used in the electrophoretic mobility shift assay. Electrophoretic mobility shift assay revealed a specific set of protein-DNA complexes when nuclear extracts prepared from IMRSV were incubated with 32P-labeled oligonucleotide probes A and B (Fig. 8, A and B). Two intense complexes, designated as complex R1 and complex R2, bound to oligonucleotide A. The specificity of these protein-DNA interactions was confirmed by increasing inhibition of binding in the presence of a 50- and 100-fold molar excess of unlabeled oligonucleotide A and no, or minimal, inhibition in the presence of excess of unlabeled unrelated consensus sequence such as SP-1, AP-3 (Stratagene). To further explore the specificity of the nuclear factor binding to probe A, an unlabeled mutant oligonucleotide (M-1), in which a NF-1-like site was mutated, was employed as competitor in the binding assay. As shown in Fig. 8A, the unlabeled mutated A competed as efficiently as the wild type A for the formation of the two specific complexes. This suggests that the mutated nucleotides are not crucial for the formation of the two specific complexes. For further confirmation, the NF-1 consensus oligonucleotide, CTF (from Stratagene), was used as competitor in the binding assay. The NF-1 consensus oligonucleotide failed to inhibit the formation of the two specific complexes. This observation suggests that the two specific complexes are not formed by an NF-1 factor.
|
Induction of Human BKB1 Receptor Gene Transcription--
LPS,
TNF-, PMA, and BK effectors have been determined to up-regulate
BKB1 gene expression by our laboratory and others (7, 8,
14). To assess inducible features of the full-length 1.8-kb promoter,
we transiently transfected IMRSV cells with the pGL-3 construct
containing the 1.8-kb full-length BKB1 promoter. At 48 h after transfection the cells were treated with LPS, TNF-
, PMA, or
BK for 4 h. The cell extracts were harvested and luciferase activity was determined. Results, as shown in Fig.
9, demonstrate that BK stimulated
luciferase activity by more than 2-fold over basal with a
p value of less than 0.01. LPS, TNF-
, or PMA showed some stimulation of luciferase activity. But the activation did not
prove to be statistically significant.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The 5'-flanking regulatory region of the BKB1 receptor gene was studied previously in some detail in our laboratory (6). The 361-bp functional promoter showed the presence of a typical TATA box, SP-1, AP-1, cAMP-response element binding protein, and cAMP-response element consensus sequences. In the present study, we extended the 5'-flanking region to a 1.8-kb fragment to further characterize the function of the promoter and identify potential domains involved in transcriptional regulation of this gene. Chimeric constructs were generated and their promoter activities were examined in transiently transfected IMRSV cells. Several distinct regulatory regions were found to be important. A dominant region, PRE, proved to function as a powerful enhancer. An adjacent region, NRE, 78-bp upstream of the PRE, functioned as a silencer.
To determine whether the PRE is a classic enhancer, it was inserted into the pGL-3 vector driven by a TK promoter in various orientations and positionings. All of these constructs generated large increases in luciferase activity. To our surprise, the placement of the PRE at the 3'-end of the luciferase gene actually doubled the enhancer capability to activate when compared with the constructs where the PRE was located at the 5'-end of the luciferase gene. It is unclear why we are finding this considerably higher induction of the reporter gene when the PRE is located at the 3'-end of the luciferase gene. However, interestingly, recently reported studies indicate that, in the presence of an enhancer, genes must exist in a supercoiled, looped, conformation to be actively transcribed (21, 22). Thus protein-protein interactions in vitro between a distal enhancer and a proximal promoter may be favored in a supercoiled DNA because of topological constraints (21, 22). The placement of the enhancer at the 3'-end of the luciferase gene may be favoring protein-protein interaction between transcription factors associated with the BKB1 enhancer and the TK promoter.
Deletion studies showed that the nucleotide sequences in the 5'- and 3'-end of the enhancer element are critical for full enhancer activation. Computer analysis of the consensus sequences in the enhancer region found a few common transcription factor-binding sites such as an NF-1-like site, an AP-1 site, and two PEA-3 sites located in the 5'- and 3'-ends of the enhancer element. Mutation and deletion studies focused on these binding sites. Mutation of motif A (NF-1-like site) of the enhancer resulted in a greater than 80% reduction of relative luciferase activity in IMRSV cells, illustrating that motif A is crucial to the enhancer. However, the NF-1 consensus sequence failed to compete with probe A in the formation of the complex. Also, a mutant oligonucleotide of the NF-1-like sequence competed with probe A in the formation of this complex. These data indicate that this complex is not binding to a classic NF-1 factor. Further studies are necessary to identify this putative factor.
Mutation within motif B (AP-1) basically abolished the enhancer activity. This motif was then confirmed to bind an AP-1 factor by gel mobility supershift assay. These results in sum suggest that the AP-1 motif plays a dominant role in the transcriptional activation of the BKB1 receptor gene. Mutation of motif D (PEA-3B) reduced the enhancer activity by 38% of the wild type. Whereas, mutation of motif C (PEA-3A) of the enhancer did not show a meaningful effect on enhancer activity. The partial inhibition by PEA-3B mutant suggests that PEA-3B plays a role in the transactivation of the enhancer. Further studies are needed to determine whether the PEA-3A element plays a co-factor role and cooperates with other factors, especially with motif A, to activate the enhancer in response to effectors.
AP-1 and PEA-3 sites have been shown to interact and cooperate to activate basal and inducible expression of the metalloproteinase (MMPs) gene family, tissue inhibitor of metalloproteinases gene family and the urokinase-type plasminogen activator gene (23-29). Notably, the BKB1 receptor gene shares certain similarities with the MMPs gene family. For example, both are inducible genes, which are up-regulated by effectors such as cytokines and growth factors (3, 7, 8, 12-14, 23). Both are rapidly induced during inflammation (3, 7, 8, 23). The two exhibit a high degree of similarity in their cis-acting regulatory elements in the 5'-flanking region, especially in the positioning of AP-1 and PEA-3 sites (23). Both genes have PEA-3 elements adjacent to the proximal AP-1 site and/or more distal AP-1 sites (23). Both genes demonstrate cell-type specific expression (23). The AP-1 and PEA-3 sites have been shown to play an important collaborative role in cell-type specific expression in the MMPs gene family (23). This coordinate and cell-type specific expression by AP-1 and PEA-3 is also found in the human urokinase-type plasminogen activator gene (24, 28, 29). In the present study, strong luciferase activity of BKB1 enhancer were observed in IMR90 and IMRSV cells, but not in HEK-293, Rat-1, or COS cells, illustrating the cell-type specific feature of this enhancer.
Furthermore, both the BKB1 and MMPs genes are induced by
PMA stimulation (14, 23). The AP-1 and PEA-3 have been demonstrated as
the responsive elements to PMA in the MMPs gene family and in the
collagenase gene (23, 26, 27). On the other hand, NF-B has also been
reported to be involved in the activation by PMA in a number of other
genes such as granulocyte-macrophage colony stimulating factor,
urokinase-type plasminogen activator, interleukin-1
, and
intercellular adhesion molecule-1 genes (30-33). Furthermore, NF-
B
and AP-1 have been reported to synergistically transactivate the
expression of the granulocyte-macrophage colony stimulating factor gene
(30). We recently reported that PMA increases the steady state mRNA
level of BKB1 receptor gene and consequently induces an
increase in [des-Arg10]kallidin binding. We found that
the NF-
B activation inhibitor, pyrrolidinedithiocarbamate,
inhibited the PMA induced increase in mRNA level of the
BKB1 gene in IMR90 cells (14). AP-1, NF-
B, and PEA-3
sites have been located in the promoter of BKB1 gene by
computer analysis. However, PMA did not elicit significant changes in
luciferase activity in IMRSV transiently transfected with the 1.8-kb
full-length BKB1 promoter. DeClerck et al. (25) reported that the promoter of human tissue inhibitor of
metalloproteinases-2 gene failed to respond to PMA stimulation,
despite the presence of AP-1 sites in the promoter region. They
concluded that the positioning of the AP-1 site is crucial in response
to PMA stimulation (25).
In the induction study of this gene promoter, BK generated more than a
2-fold increase of luciferase activity, but LPS, TNF-, and PMA did
not show significant increase of the luciferase activity compared with
basal luciferase levels. These data suggest that different stimulators
require different sizes of promoter or different regulatory elements to
induce the transcription of the gene. Thus, a larger promoter
construct, longer than 1.8 kb may be required to obtain significant
inducibility by LPS, TNF-
, and PMA stimulation. Another possibility
is that the differences in signal transduction between the native
promoter, with the target gene in vivo, and the chimeric
promoter, transiently transfected and linked to a luciferase gene, may
be critical to the insensitivity in response to LPS, TNF-
, and PMA
stimulation by the transfected BKB1 promoter.
Under normal, steady state conditions, the expression of this gene is tightly regulated by its native promoter, enhancer, and other regulatory elements. Results from transient transfection in IMR90 and IMRSV cells indicate that the expression of reporter gene luciferase is heavily inhibited by the upstream silencer of BKB1 receptor gene, and can be induced by removing the silencer from the immediate upstream left of the enhancer. This observation is entirely consistent with the minimal expression of the BKB1 receptor under normal physiological conditions, and rapidly inducible expression during inflammation. It provides a distinct transactivation model for expression and up-regulation of this gene by extracellular effectors.
In summary, we have characterized the functional promoter region and identified a cell-type specific enhancer in the 5'-flanking region of the human BKB1 receptor gene. An AP-1 transcription factor and another, unknown, factor appear crucial for full enhancer activity. We are also finding that a silencer directly suppresses the enhancer activity in IMR90 and IMRSV. This study paves the way for further analysis of the mechanisms involved in the transcriptional regulation of a gene which is rapidly induced under pathological conditions such as toxic sepsis which result in inflammation, hypotension, and pain.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Ned Rich and his staff at DNA/Protein Analysis Core for their expertise in sequencing and oligonucleotide synthesis, and Dr. Gregory N. Prado for expert technical assistance in binding assay.
![]() |
FOOTNOTES |
---|
* This work was supported by NHLBI Grant HL25776 and NIA Training Grant A600115, National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) U48827.
To whom correspondence should be addressed. Tel.: 617-638-4717;
Fax: 617-638-5339; E-mail: peterp{at}bu.edu.
1
The abbreviations used are: BK, bradykinin; PRE,
positive regulatory element; NRE, negative regulatory element; IMRSV,
SV-40 transformed IMR90 cells; AP, activator protein; NF, nuclear
factor; PEA-3, polyomavirus enhancer A-binding protein 3; bp, base
pair(s); kb, kilobase pair(s); HEK-293, human embryonal kidney 293 cells; TK, thymidine kinase; MMPs, metalloproteinases; PMA, phorbol
myristate acetate; LPS, lipopolysaccharide; TNF-, tumor necrosis
factor-
; PCR, polymerase chain reaction.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|